- ASML Holding NV (NASDAQ:ASML) reported a fourth-quarter FY22 net sales growth of 29% year-on-year to €6.43 billion.
- The Q4 net bookings were €6.32 billion versus €7.05 billion a year ago. The gross margin contracted by 270 bps Y/Y to 51.5%.
- Also Read: ASML Chief Voices How US Gained With Semiconductor Embargo Against China At Cost Of ASML
- GAAP EPS was €4.60 versus €4.38 a year earlier.
- ASML held €7.38 billion in cash and equivalents.
- Buybacks & Dividends: In Q4, ASML bought €300 million in shares. ASML looks to boost FY22 total dividend by 5.5% to €5.80 per ordinary share.
- ASML CEO Peter Wennink said, “We continue to see uncertainty in the market caused by inflation, rising interest rates, risk of recession, and geopolitical developments related to export controls. However, our customers indicate that they expect the market to rebound in the second half of the year.”
- Q1 Outlook: ASML sees net sales of €6.1 billion – €6.5 billion and a 49% – 50% gross margin.
- ASML expects 2023 net sales to grow over 25% Y/Y.
- Last November, ASML updated its view on demand outlook, capacity plans, and business model at the Investor Day meeting.
- ASML expects 2025 annual revenue between approximately €30 billion – €40 billion with a gross margin between 54% – 56%.
- ASML sees 2030 annual revenue between approximately €44 billion – €60 billion, with a gross margin between about 56% – 60%.
- Price Action: ASML shares closed lower by 0.89% at $670.01 on Tuesday.
Vaxcyte Doses First Participants In Phase 1/2 Clinical Study Evaluating VAX-31 For The Prevention Of Invasive Pneumococcal Disease In Adults
-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Half of 2024 ----
